Clinical Trials

90 enrolled 19 charts

Prostatic Neoplasms

NCT04034927 2026-03-18

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT04394858 2026-03-18

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

46 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04548752 2026-03-18

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03598257 2026-03-17

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

300 enrolled

Phase 1 Active not recruiting

Inflammatory Breast Neoplasms

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

28 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

21 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06909825 2026-03-05

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

85 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04884360 2026-03-02

MONO-OLA1

366 enrolled

Ovarian Neoplasms

NCT04742075 2026-02-27

DOVACC

188 enrolled

Phase EARLY_PHASE1 Active not recruiting

Ovarian Neoplasms

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

15 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 1 Active not recruiting

63 enrolled

Sarcoma

Osteosarcoma

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

10 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02264678 2026-02-20

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

357 enrolled

Ovarian Neoplasms

NCT04065269 2026-02-20

ATARI

174 enrolled

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03212274 2026-02-19

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

89 enrolled

CNSGastrointestinal

Glioblastoma, Glioma, Cholangiocarcinoma

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

96 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03742895 2026-02-18

MK-7339-002

326 enrolled

Advanced Solid Neoplasms

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

96 enrolled